LUDWIG ENTERPRISES - LUDG STOCK NEWS

Ludwig Enterprises (OTC PINK:LUDG) has filed a provisional patent for a novel cancer detection method called 'mRNAs Differentially Expressed in Cancer.' The breakthrough technology uses a six-mRNA gene combination that shows enhanced sensitivity and specificity in breast cancer detection. The development is based on research involving over 3,300 cheek cell samples from 40 U.S. medical centers, where AI analyzed more than 12 million combinations of a 48-gene mRNA microarray. The company plans to rebrand as Revealia™ in 2024, subject to regulatory approvals.

Ludwig Enterprises (OTC PINK:LUDG) announces Revealia™, a revolutionary AI-powered cancer screening technology. This mail-order, non-invasive cheek swab test aims to detect early signs of cancer using advanced artificial intelligence and machine learning.

The core of Revealia™ is the Revealia Inflammatory Index (RII), which quantifies cancer risk by analyzing mRNA-based genetic signals. The AI technology continuously improves its accuracy by learning from an expanding dataset collected from over 40 multipurpose medical clinics across the United States.

Key features of the AI approach include optimizing sensitivity and specificity trade-offs and continuous learning. Dr. Marvin S. Hausman, CSO, and Kyle Ambert, a member of Ludwig's Scientific Advisory Board, highlight the potential of this technology to revolutionize early cancer detection and screening.

Ludwig Enterprises Inc. (OTC PINK:LUDG) has announced Revealia™, an AI-powered cancer screening technology. This revolutionary mail-order non-invasive cheek swab test aims to transform early cancer detection with continuously improving accuracy. At its core is the Revealia Inflammatory Index (RII), which uses advanced AI to analyze mRNA-based genetic signals associated with cancer presence.

Developed by Dr. Kyle Ambert, PhD, Director of Data Science at Nike's Consumer Data Science Division, the AI technology employs machine learning algorithms that continuously update and improve as new patient data is received. Key features include optimization of sensitivity and specificity trade-offs, continuous learning from an expanding dataset, and analysis of mRNA samples from over 40 multipurpose medical clinics across the United States.

Ludwig Enterprises (OTC PINK:LUDG) has acquired intellectual property and patents for mRNA Neuro Panel and Serotonin Assay, including accumulated test data. This acquisition enables the use of mRNA genetic biomarkers to study brain inflammation in diseases like autism, PTSD, Parkinson's, and Alzheimer's. The company has also acquired breakthrough technology for measuring serotonin levels in salivary exosomes. The acquisition includes a U.S. Patent Application, international publication, serotonin assays developed at the University of Central Florida, and work product from Autism Spectrum Disorder and Fragile X Syndrome studies. Ludwig plans to start its screening business with breast cancer and expand to other diseases.

Nova Mentis Life Science Corp. (NMLSF) has entered into an intellectual property conveyance agreement with Ludwig Enterprises Inc. and Dr. Marvin S. Hausman. NOVA will assign its mRNA Neuro Panel and Serotonin Assay intellectual property to Ludwig. In exchange, Hausman will forgive NOVA's $245,712 debt, and Ludwig will issue 750,000 restricted common shares to NOVA. Additionally, NOVA will receive a 10-year royalty of 2.5% on revenue up to $245,712 and 5% thereafter from the Property's commercialization.

NOVA's Health Canada Phase 2a clinical trial for Fragile X Syndrome has faced recruitment challenges, with no candidates meeting enrollment requirements. The company's Board is actively seeking new business opportunities in the Life Sciences sector to create shareholder value.

Ludwig Enterprises, Inc. (OTC PINK:LUDG) has announced significant corporate initiatives as it prepares to launch Revealia™, its innovative cancer screening test, in 2024. The company plans to change its name to Revealia™, Inc. and apply for OTCQB listing, with aspirations for higher listings like NASDAQ or CBOE in the future. Revealia™ is positioned as the world's most convenient cancer screening test, utilizing a simple mail-order noninvasive cheek swab.

The company has collected over 3000 mRNA samples from multiple medical clinics across the US and employs proprietary machine learning AI technology for continuous statistical updates. CEO Marvin S. Hausman, MD, states that Ludwig has uncovered potentially game-changing mRNA-based genetic signals associated with cancer presence.

Ludwig Enterprises has filed a provisional patent for an mRNA genetic screening technique targeting breast, colon, and bladder cancers. The innovation focuses on identifying and differentiating cancers and assessing treatment effectiveness through mRNA biomarkers. These biomarkers are dynamic genetic signals that can revolutionize cancer diagnostics. The company is leveraging machine learning AI to continuously update statistical models using patient data from over 40 clinics in the U.S. CEO Marvin S. Hausman highlighted the significance of the breakthrough in tapping into the billion-dollar cancer diagnostic market. Cheek cell samples, collected noninvasively, are analyzed to detect these mRNA biomarkers.